EDGAR Filing Documents for 0001104659-18-018344

Form S-3 - Registration statement under Securities Act of 1933:

SEC Accession No. 0001104659-18-018344

Filing Date

2018-03-16

Accepted

2018-03-16 17:05:44

Documents

Document Format Files

Seq	Description	Document	Type	Size
1	S-3	a18-8166_1s3.htm	S-3	587725
2	EX-4.2	a18-8166_1ex4d2.htm	EX-4.2	444405
3	EX-4.3	a18-8166_1ex4d3.htm	EX-4.3	462261
4	EX-4.4	a18-8166_1ex4d4.htm	EX-4.4	57593
5	EX-4.5	a18-8166_1ex4d5.htm	EX-4.5	57253
6	EX-5.1	a18-8166_1ex5d1.htm	EX-5.1	39419
7	EX-12.1	a18-8166_1ex12d1.htm	EX-12.1	58910
8	EX-23.1	a18-8166_1ex23d1.htm	EX-23.1	4179
9	EX-23.2	a18-8166_1ex23d2.htm	EX-23.2	4769
10	GRAPHIC	g81661bci001.jpg	GRAPHIC	4006
11	GRAPHIC	g81661kzi001.jpg	GRAPHIC	2465
	Complete submission text file	0001104659-18-018344.txt		1726788

Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406

Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640

Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)